Eli Lilly | LLY - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 7.61B 2.04B 2026-06
Abbott USD 2.39B 27M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Baxter International USD 362M 368M 2026-06
Biogen USD 647.3M 269.6M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Coherus Biosciences USD -46.35M 90.86M 2025-12
Drreddys Laboratories INR 2B 13.43B 2026-03
Eli Lilly USD 8.85B 583.8M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
J&J USD 8.66B 839M 2026-06
Medtronic USD 2.45B 1.04B 2026-03
Merck USD -3.53B 6.95B 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Novartis USD 3.84B 1.33B 2026-03
Novo Nordisk DKK 33.8B 3.23B 2025-06
Perrigo USD 105.4M 513.9M 2026-06
Pfizer USD -653M 5.84B 2026-06
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 64.77M 2.96M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 837M 1.17B 2026-06
Sanofi EUR 2B 3.16B 2026-03
United Therapeutics USD 372.7M 54.4M 2026-06
Zoetis USD 758M 3M 2026-03